Phase 1 Study to Evaluate the Safety and Tolerability of EO1404 in the Treatment of Corneal Edema
NCT ID: NCT04191629
Last Updated: 2019-12-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
35 participants
INTERVENTIONAL
2016-05-04
2021-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
50K to 200K cells
EO1404
50K to 200K cells with endothelial brushing
EO1404
Endothelial brushing or Descemet stripping
500K cells
EO1404
500K cells with endothelial brushing
EO1404
Endothelial brushing or Descemet stripping
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EO1404
Endothelial brushing or Descemet stripping
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Pseudophakic with a posterior chamber intraocular lens.
3. Symptomatic corneal edema associated with endothelial dysfunction which may be secondary to Fuchs corneal dystrophy or pseudophakic bullous keratopathy.
a Symptoms including reduced vision and/or glare, and/or pain; subject may or may not have been on topical therapies such as 5% sodium chloride drops or prednisolone acetate 1% drops.
b ETDRS-best corrected visual acuity worse than 20/63 on Snellen. c Central corneal thickness \< 2 mm by ultrasound pachymetry or OCT. d Subject must have progressed far enough in their clinical course to be considered a surgical candidate for full-thickness corneal transplantation or endothelial keratoplasty.
4. Subject must understand and sign the informed consent. If the subject's vision is impaired to the point where he/she cannot read the informed consent document, the document will be read to the subject in their maternal language.
5. Subject must be medically able and willing to undergo the protocol-required procedures.
Exclusion Criteria
1. Other corneal disease, including active or prior herpetic ocular infection; active inflammation; corneal scarring from trauma, burns, or infection; or band keratopathy.
2. Visual acuity in the fellow eye is worse than 20/200.
3. Anterior chamber intraocular lens.
4. Subject requires topical, intravenous or oral acyclovir and/or related products during study duration
5. History of vitrectomy.
6. History of refractive surgery.
7. Macular disease that in the investigator and/or sponsor's opinion would limit the ability of the subject to demonstrate improvement in BCVA.
8. Prior incisional eye surgery within 3 months prior to study treatment.
9. Subject is receiving systemic steroids or other systemic immunosuppressive medications.
10. Subject is currently participating in or has participated within the last 3 months in any other clinical trial of an investigational drug by ocular or systemic administration.
11. History of uveitis or other ocular inflammatory disease.
12. History of glaucoma, or peripheral anterior synechiae on gonioscopy.
13. History of incisional glaucoma surgery (e.g., trabeculectomy, glaucoma drainage implant).
14. Female subject who is pregnant, nursing, or planning to become pregnant, or who is of childbearing potential and not using a reliable means of contraception during the study.
15. Subject is immunodeficient, or tested positive for HIV.
16. Subject is on chemotherapy.
17. History of malignancy other than basal cell carcinoma, UNLESS the malignancy was treated successfully 5 years prior to inclusion in the study.
18. History of ocular neoplasm.
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Emmecell
INDUSTRY
Valeria Sanchez-Huerta
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Valeria Sanchez-Huerta
Academic Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Valeria Sanchez-Huerta, MD
Role: PRINCIPAL_INVESTIGATOR
Asociacion Para Evitar la Ceguera
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Asociación Para Evitar la Ceguera en México, IAP, Hospital "Dr. Luis Sánchez Bulnes"
Mexico City, , Mexico
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Sanchez-Huerta Valeria, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VSH01
Identifier Type: -
Identifier Source: org_study_id